Show simple item record

dc.contributor.authorFeldinger, Ken
dc.contributor.authorGenerali, Den
dc.contributor.authorKramer-Marek, Gen
dc.contributor.authorGijsen, Men
dc.contributor.authorNg, TBen
dc.contributor.authorWong, JHen
dc.contributor.authorStrina, Cen
dc.contributor.authorCappelletti, Men
dc.contributor.authorAndreis, Den
dc.contributor.authorLi, J-Len
dc.contributor.authorBridges, Een
dc.contributor.authorTurley, Hen
dc.contributor.authorLeek, Ren
dc.contributor.authorRoxanis, Ien
dc.contributor.authorCapala, Jen
dc.contributor.authorMurphy, Gen
dc.contributor.authorHarris, ALen
dc.contributor.authorKong, Aen
dc.date.accessioned2016-08-09T14:57:51Z
dc.date.available2016-08-09T14:57:51Z
dc.date.issued2014-08-30en
dc.identifier.urihttp://hdl.handle.net/10026.1/5250
dc.description.abstract

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab treatment. Beside ADAM17, ADAM10 is the other well characterized ADAM protease responsible for HER ligand shedding. Therefore, we studied the role of ADAM10 in relation to trastuzumab treatment and resistance in HER2 positive breast cancer. ADAM10 expression was assessed in HER2 positive breast cancer cell lines and xenograft mice treated with trastuzumab. Trastuzumab treatment increased ADAM10 levels in HER2 positive breast cancer cells (p ≤ 0.001 in BT474; p ≤ 0.01 in SKBR3) and in vivo (p ≤ 0.0001) compared to control, correlating with a decrease in PKB phosphorylation. ADAM10 inhibition or knockdown enhanced trastuzumab response in naïve and trastuzumab resistant breast cancer cells. Trastuzumab monotherapy upregulated ADAM10 (p ≤ 0.05); and higher pre-treatment ADAM10 levels correlated with decreased clinical response (p ≤ 0.05) at day 21 in HER2 positive breast cancer patients undergoing a trastuzumab treatment window study. Higher ADAM10 levels correlated with poorer relapse-free survival (p ≤ 0.01) in a cohort of HER2 positive breast cancer patients. Our studies implicate a role of ADAM10 in acquired resistance to trastuzumab and establish ADAM10 as a therapeutic target and a potential biomarker for HER2 positive breast cancer patients.

en
dc.format.extent6633 - 6646en
dc.languageengen
dc.language.isoengen
dc.subjectADAM Proteinsen
dc.subjectADAM10 Proteinen
dc.subjectAmyloid Precursor Protein Secretasesen
dc.subjectAnimalsen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntineoplastic Agentsen
dc.subjectBreast Neoplasmsen
dc.subjectCell Line, Tumoren
dc.subjectCell Proliferationen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectFemaleen
dc.subjectGene Knockdown Techniquesen
dc.subjectHumansen
dc.subjectMembrane Proteinsen
dc.subjectMiceen
dc.subjectReceptor, ErbB-2en
dc.subjectTrastuzumaben
dc.subjectXenograft Model Antitumor Assaysen
dc.titleADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/24952873en
plymouth.issue16en
plymouth.volume5en
plymouth.publication-statusPublisheden
plymouth.journalOncotargeten
dc.identifier.doi10.18632/oncotarget.1955en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeUnited Statesen
dc.identifier.eissn1949-2553en
dc.rights.embargoperiodNot knownen
rioxxterms.versionofrecord10.18632/oncotarget.1955en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV